BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 31027690)

  • 1. A molecular graded prognostic assessment (molGPA) model specific for estimating survival in lung cancer patients with leptomeningeal metastases.
    Yin K; Li YS; Zheng MM; Jiang BY; Li WF; Yang JJ; Tu HY; Zhou Q; Zhong WZ; Yang XN; Chen HJ; Yan HH; Li LL; Wu YL; Zhang XC
    Lung Cancer; 2019 May; 131():134-138. PubMed ID: 31027690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA).
    Sperduto PW; Yang TJ; Beal K; Pan H; Brown PD; Bangdiwala A; Shanley R; Yeh N; Gaspar LE; Braunstein S; Sneed P; Boyle J; Kirkpatrick JP; Mak KS; Shih HA; Engelman A; Roberge D; Arvold ND; Alexander B; Awad MM; Contessa J; Chiang V; Hardie J; Ma D; Lou E; Sperduto W; Mehta MP
    JAMA Oncol; 2017 Jun; 3(6):827-831. PubMed ID: 27892978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applicability of the lung-molGPA index in non-small cell lung cancer patients with different gene alterations and brain metastases.
    Chen K; Yu X; Zhang F; Xu Y; Zhang P; Huang Z; Fan Y
    Lung Cancer; 2018 Nov; 125():8-13. PubMed ID: 30429042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical characteristic and prognostic factors of leptomeningeal metastasis in patients with non-small-cell lung cancer-a retrospective study from one single cancer institute.
    Yan W; Jing W; An N; Tian Y; Guo D; Kong L; Zhu H; Yu J
    Cancer Med; 2019 Jun; 8(6):2769-2776. PubMed ID: 30993909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Retrospective Real-World Study of Prognostic Factors Associated With EGFR Mutated Lung Cancer With Leptomeningeal Metastasis.
    Wu Y; Zhao Y; Wu Y; Chen H; Ma S; Wang Q
    Clin Lung Cancer; 2024 Jun; 25(4):347-353.e1. PubMed ID: 38418264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis.
    Kuiper JL; Hendriks LE; van der Wekken AJ; de Langen AJ; Bahce I; Thunnissen E; Heideman DA; Berk Y; Buijs EJ; Speel EJ; Krouwels FH; Smit HJ; Groen HJ; Dingemans AM; Smit EF
    Lung Cancer; 2015 Sep; 89(3):255-61. PubMed ID: 26117231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group.
    Umemura S; Tsubouchi K; Yoshioka H; Hotta K; Takigawa N; Fujiwara K; Horita N; Segawa Y; Hamada N; Takata I; Yamane H; Kamei H; Kiura K; Tanimoto M
    Lung Cancer; 2012 Jul; 77(1):134-9. PubMed ID: 22487432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pemetrexed in the Treatment of Leptomeningeal Metastasis in Patients With EGFR-mutant Lung Cancer.
    Choi M; Keam B; Ock CY; Kim M; Kim TM; Kim DW; Heo DS
    Clin Lung Cancer; 2019 Jul; 20(4):e442-e451. PubMed ID: 31010639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of Lung Adenocarcinoma With Leptomeningeal Metastases: A 2022 Targeted-Therapy-Assisted molGPA Model.
    Zhang M; Tong J; Ma W; Luo C; Liu H; Jiang Y; Qin L; Wang X; Yuan L; Zhang J; Peng F; Chen Y; Li W; Jiang Y
    Front Oncol; 2022; 12():903851. PubMed ID: 35795063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applicability of the adjusted graded prognostic assessment for lung cancer with brain metastases using molecular markers (Lung-molGPA) in a Chinese cohort: A retrospective study of multiple institutions.
    Zhang T; Zhang Y; Zhou L; Deng S; Huang M; Liu Y; Liu Y; Gong Y; Zhu J; Xue J; Bai Y; Ma H; Zhang Y; Yu M; Li Y; Wang Y; Zou B; Zhou X; Xiu W; Na F; Xu Y; Peng F; Wang J; Lu Y
    Cancer Med; 2020 Dec; 9(23):8772-8781. PubMed ID: 33027555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leptomeningeal metastasis after effective first-generation EGFR TKI treatment of advanced non-small cell lung cancer.
    Wu YL; Zhao Q; Deng L; Zhang Y; Zhou XJ; Li YY; Yu M; Zhou L; Zou BW; Lu Y; Liu YM
    Lung Cancer; 2019 Jan; 127():1-5. PubMed ID: 30642536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast cancer patients with brain metastases or leptomeningeal disease: 10-year results of a national cohort with validation of prognostic indexes.
    Znidaric T; Gugic J; Marinko T; Gojkovic Horvat A; Paulin Kosir MS; Golo D; Ivanetic Pantar M; Ratosa I
    Breast J; 2019 Nov; 25(6):1117-1125. PubMed ID: 31286623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole brain radiation therapy does not improve the overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastasis.
    Yan W; Liu Y; Li J; Han A; Kong L; Yu J; Zhu H
    Radiat Oncol; 2019 Sep; 14(1):168. PubMed ID: 31521171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of the graded prognostic assessment for lung cancer with brain metastases using molecular markers (lung-molGPA).
    Nieder C; Hintz M; Oehlke O; Bilger A; Grosu AL
    Radiat Oncol; 2017 Jun; 12(1):107. PubMed ID: 28651600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments.
    Zheng MM; Tu HY; Yang JJ; Zhang XC; Zhou Q; Xu CR; Jiang BY; Yang XN; Yang XR; Deng JY; Yang MY; Xu BF; Chen XM; Li YS; Wu YL
    Eur J Cancer; 2021 Jun; 150():23-30. PubMed ID: 33882375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted Therapies and Utility of the Lung-molGPA in Non-Small-Cell Lung Cancer Patients with Brain Metastases.
    Cacho-Díaz B; Cuapantécatl LD; Garcilazo-Reyes YJ; Cabrera-Miranda L; Hernandez-Martinez JM; Arrieta O
    Oncology; 2022; 100(10):542-554. PubMed ID: 35988535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Craniospinal irradiation(CSI) in patients with leptomeningeal metastases: risk-benefit-profile and development of a prognostic score for decision making in the palliative setting.
    Devecka M; Duma MN; Wilkens JJ; Kampfer S; Borm KJ; Münch S; Straube C; Combs SE
    BMC Cancer; 2020 Jun; 20(1):501. PubMed ID: 32487151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Epidermal growth factor tyrosine kinase inhibitors used in the treatment of NSCLC patients with leptomeningeal metastasis].
    Xu Y; Zhong W; Zhao J; Chen MJ; Zhang L; Li LY; Wang MZ
    Zhonghua Zhong Liu Za Zhi; 2016 Dec; 38(12):920-924. PubMed ID: 27998469
    [No Abstract]   [Full Text] [Related]  

  • 19. Prognostic indices in stereotactic radiotherapy of brain metastases of non-small cell lung cancer.
    Kaul D; Angelidis A; Budach V; Ghadjar P; Kufeld M; Badakhshi H
    Radiat Oncol; 2015 Nov; 10():244. PubMed ID: 26611493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA).
    Sperduto PW; Jiang W; Brown PD; Braunstein S; Sneed P; Wattson DA; Shih HA; Bangdiwala A; Shanley R; Lockney NA; Beal K; Lou E; Amatruda T; Sperduto WA; Kirkpatrick JP; Yeh N; Gaspar LE; Molitoris JK; Masucci L; Roberge D; Yu J; Chiang V; Mehta M
    Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):812-816. PubMed ID: 29063850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.